FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1811627814> ?p ?o ?g. }

• W1811627814 abstract "Pemetrexed and epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) were used in patients with EGFR mutation to determine their effects. This study analyzed the influence of EGFR-TKIs on pemetrexed by observing the clinical efficacy and toxicity of pemetrexed following responses to EGFR-TKIs.Pulmonary adenocarcinoma patients were divided into EGFR-TKIs and no-EGFR-TKI groups according to the targeted therapy. All patients received pemetrexed (500 mg/m2) as second (or higher)-line treatment. The Response Evaluation Criteria in Solid Tumors (version 1.0) were used to evaluate the response to pemetrexed. Adverse events were classified based on version 4.0 of the National Cancer Institute Common Toxicity Criteria.There were 57 patients in the EGFR-TKIs group and 56 in the no-EGFR-TKIs group. The disease control rates (DCRs) were 77.2% and 67.9% (P=0.367). The progression free survival (PFS) periods were 5.95 and 3.55 months (P=0.535). The overall survival (OS) periods were 10.10 and 8.24 months (P=0.432). However, these values were not statistically significant. The common toxicities of pemetrexed were hematologic and gastrointestinal (grades I and II). Two patients in the EGFR-TKIs group discontinued pemetrexed because of severe toxicities, which were not observed in the no-EGFR-TKIs group. Both groups had one patient who reduced dosage because of myelosuppression (grade IV). There were five and nine patients in the EGFR-TKIs and no-EGFR-TKIs groups, respectively, who delayed therapy not because of severe toxicities but due to subjective factors.The DCRs, PFS periods, and OS periods of the patients administered with pemetrexed following EGFR-TKIs were better than those of the EGFR-TKIs group, but the differences were not statistically significant. Therefore, sequential pemetrexed administration caused negligible toxicities and can be used in adenocarcinoma therapy following responses to EGFR-TKIs." @default.
• W1811627814 created "2016-06-24" @default.
• W1811627814 creator A5002040792 @default.
• W1811627814 creator A5004226726 @default.
• W1811627814 creator A5004273106 @default.
• W1811627814 creator A5028624269 @default.
• W1811627814 creator A5055526321 @default.
• W1811627814 creator A5084055143 @default.
• W1811627814 date "2012-05-01" @default.
• W1811627814 modified "2023-09-26" @default.
• W1811627814 title "[Effects of EGFR-TKIs on sequential pemetrexed
for advanced pulmonary adenocarcinoma]." @default.
• W1811627814 cites W1968941521 @default.
• W1811627814 cites W2018586174 @default.
• W1811627814 cites W2062951393 @default.
• W1811627814 cites W2083189837 @default.
• W1811627814 cites W2083702866 @default.
• W1811627814 cites W2095618958 @default.
• W1811627814 cites W2101995865 @default.
• W1811627814 cites W2134667653 @default.
• W1811627814 cites W2135192471 @default.
• W1811627814 cites W2138503145 @default.
• W1811627814 cites W2145842917 @default.
• W1811627814 cites W2171689249 @default.
• W1811627814 doi "https://doi.org/10.3779/j.issn.1009-3419.2012.05.08" @default.
• W1811627814 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6000128" @default.
• W1811627814 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22613336" @default.
• W1811627814 hasPublicationYear "2012" @default.
• W1811627814 type Work @default.
• W1811627814 sameAs 1811627814 @default.
• W1811627814 citedByCount "0" @default.
• W1811627814 crossrefType "journal-article" @default.
• W1811627814 hasAuthorship W1811627814A5002040792 @default.
• W1811627814 hasAuthorship W1811627814A5004226726 @default.
• W1811627814 hasAuthorship W1811627814A5004273106 @default.
• W1811627814 hasAuthorship W1811627814A5028624269 @default.
• W1811627814 hasAuthorship W1811627814A5055526321 @default.
• W1811627814 hasAuthorship W1811627814A5084055143 @default.
• W1811627814 hasConcept C121608353 @default.
• W1811627814 hasConcept C126322002 @default.
• W1811627814 hasConcept C143998085 @default.
• W1811627814 hasConcept C197934379 @default.
• W1811627814 hasConcept C2776256026 @default.
• W1811627814 hasConcept C2776694085 @default.
• W1811627814 hasConcept C2777240266 @default.
• W1811627814 hasConcept C2778239845 @default.
• W1811627814 hasConcept C2779438470 @default.
• W1811627814 hasConcept C2781182431 @default.
• W1811627814 hasConcept C71924100 @default.
• W1811627814 hasConceptScore W1811627814C121608353 @default.
• W1811627814 hasConceptScore W1811627814C126322002 @default.
• W1811627814 hasConceptScore W1811627814C143998085 @default.
• W1811627814 hasConceptScore W1811627814C197934379 @default.
• W1811627814 hasConceptScore W1811627814C2776256026 @default.
• W1811627814 hasConceptScore W1811627814C2776694085 @default.
• W1811627814 hasConceptScore W1811627814C2777240266 @default.
• W1811627814 hasConceptScore W1811627814C2778239845 @default.
• W1811627814 hasConceptScore W1811627814C2779438470 @default.
• W1811627814 hasConceptScore W1811627814C2781182431 @default.
• W1811627814 hasConceptScore W1811627814C71924100 @default.
• W1811627814 hasLocation W18116278141 @default.
• W1811627814 hasOpenAccess W1811627814 @default.
• W1811627814 hasPrimaryLocation W18116278141 @default.
• W1811627814 isParatext "false" @default.
• W1811627814 isRetracted "false" @default.
• W1811627814 magId "1811627814" @default.
• W1811627814 workType "article" @default.